CTS-21166 is a small-molecule beta-secretase inhibitor, which is being developed as a disease-modifying treatment for Alzheimer's disease. CTS-21166 is the only BACE1 inhibitor that has passed Phase I clinical trial... In 2008, CoMentis revealed this small compound as a transition-state analog inhibitor (structure is currently undisclosed) with excellent properties in brain penetration, selectivity, metabolic stability, and oral availability; all of these have met the requirements...
- Mechanism
- Curator reviewed
Beta secretase is the enzyme thought responsible for causing Alzheimer’s. CTS-21166 is a highly selective, potent and orally active beta-secretase inhibitor.
- Primary indication
- Investigated for use/treatment in alzheimer's disease.Curator reviewed
- Code names
- CTS-21166
Resolves to
What you can answer from here — as of April 23, 2025
Which drugs share a target with CTS-21166, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account